Back to company

SYNACT PHARMA ApS: Financial statements 2020

CVR: 34459975

SYNACT PHARMA ApS (CVR 34459975) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -16,676,255 and a net result of DKK -14,002,315 compared with DKK -9,826,308 the year before. Equity amounted to DKK 11,357,224. The solvency ratio was 89.5%.

Gross Profit
-16,676,255 kr.
Profit/Loss
-14,002,315 kr.
Equity
11,357,224 kr.
Total Assets
12,691,131 kr.

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2020--16.7 mio.-14 mio.11.4 mio.-
2019--11.5 mio.-9.8 mio.-21.8 mio.-
2018--16.8 mio.-13.6 mio.-12 mio.-
2017--10 mio.-8.3 mio.1.6 mio.-
2016--9.9 mio.-8.9 mio.9.9 mio.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is SYNACT PHARMA ApS?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2020

SYNACT PHARMA ApS: The 2019 annual report is outApr 28, 2020

SYNACT PHARMA ApS has published its annual report for 2019. Gross profit came to DKK -11,468,376, and the net result was DKK -9,826,308.

About SYNACT PHARMA ApS

SYNACT PHARMA ApS is a Danish company of the type Anpartsselskab based in Holte, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named SYNACTION PHARMA ApS. The management consists of Jeppe Øvli Øvlesen, Thomas Boesen and Ann Kristin Brøgger Led. The company is owned by SynAct Pharma AB. In 2025, the company reported a gross profit of DKK -53,194,923 and a net result of DKK -59,812,937 compared with DKK -30,477,376 the year before. Equity amounted to DKK 20,295,649.